A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.

NCT00330460 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1189

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoporosis
Osteopenia

Interventions

DRUG: Alendronate
DRUG: Denosumab

Sponsor

Amgen